Palisade bio announces $2.0 million registered direct offering

Carlsbad, calif., may 06, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (the “company” or “palisade bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.
PALI Ratings Summary
PALI Quant Ranking